Ipratropium bromide

First approved in 1986

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H30NO3.Br.H2O
Molecular Weight	430.376
Optical Activity	( + / - )
Defined Stereocenters	4 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.[Br-].CC(C)[N@+]1(C)[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)C(CO)C3=CC=CC=C3

InChI

InChIKey=KEWHKYJURDBRMN-ZEODDXGYSA-M

InChI=1S/C20H30NO3.BrH.H2O/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H;1H2/q+1;;/p-1/t16-,17+,18+,19?,21+;;

HIDE SMILES / InChI

Molecular Formula	C20H30NO3
Molecular Weight	332.4571
Charge	1
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	4 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Br
Molecular Weight	79.904
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68009241

Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 168 Target ID: CHEMBL216 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2849	0.49 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2849	1.5 nM [Ki]
Muscarinic acetylcholine receptor M3 160 Target ID: CHEMBL245 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2849	0.51 nM [Ki]
Muscarinic acetylcholine receptor M4 87 Target ID: CHEMBL1821 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2849	0.66 nM [Ki]
Muscarinic acetylcholine receptor M5 63 Target ID: CHEMBL2035 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Antagonist 2849	1.7 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic obstructive pulmonary disease 175 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021527s021lbl.pdf	Primary		Approved 8583	ATROVENT HFA Approved Use ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Launch Date 2004

C_max

Value	Dose	Co-administered	Analyte	Population
33.5 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
35.4 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN
31.7 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
1.04 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
131 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: MALE food status: UNKNOWN
123 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day steady-state, respiratory dose: 20 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
95.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021747s010lbl.pdf	20 μg 4 times / day multiple, respiratory dose: 20 μg route of administration: Respiratory experiment type: MULTIPLE co-administered: ALBUTEROL	ALBUTEROL	IPRATROPIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years Health Status: unhealthy Age Group: 18 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	Disc. AE: Nasal disorder NOS, Nasal dryness... AEs leading to discontinuation/dose reduction: Nasal disorder NOS (17%) Nasal dryness (2%) Epistaxis (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	Disc. AE: Epistaxis... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	Disc. AE: Epistaxis, Upper respiratory tract infection... AEs leading to discontinuation/dose reduction: Epistaxis (1 patient) Upper respiratory tract infection (1 patient) Ear infection (1 patient) Exacerbation of asthma (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	unhealthy, mean 40.7 years Health Status: unhealthy Age Group: mean 40.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	Disc. AE: Nausea and vomiting... AEs leading to discontinuation/dose reduction: Nausea and vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/
42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	unhealthy, mean 42.6 years Health Status: unhealthy Age Group: mean 42.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	Other AEs: Nasal disorder NOS... Other AEs: Nasal disorder NOS (19 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/

AEs

AE	Significance	Dose	Population
Nasal disorder NOS	17% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years Health Status: unhealthy Age Group: 18 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis	2% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years Health Status: unhealthy Age Group: 18 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Nasal dryness	2% Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/	unhealthy, 18 - 75 years Health Status: unhealthy Age Group: 18 - 75 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751529/
Epistaxis	1 patient Disc. AE	168 ug 3 times / day steady, respiratory Highest studied dose Dose: 168 ug, 3 times / day Route: respiratory Route: steady Dose: 168 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Ear infection	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Epistaxis	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Exacerbation of asthma	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Upper respiratory tract infection	1 patient Disc. AE	84 ug 3 times / day steady, respiratory Highest studied dose Dose: 84 ug, 3 times / day Route: respiratory Route: steady Dose: 84 ug, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/	unhealthy, 2 - 5 years Health Status: unhealthy Age Group: 2 - 5 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15702820/
Nausea and vomiting	1 patient Disc. AE	200 ug single, respiratory Highest studied dose Dose: 200 ug Route: respiratory Route: single Dose: 200 ug Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/	unhealthy, mean 40.7 years Health Status: unhealthy Age Group: mean 40.7 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/2150695/
Nasal disorder NOS	19 patients	42 ug 1 times / day steady, respiratory Recommended Dose: 42 ug, 1 times / day Route: respiratory Route: steady Dose: 42 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/	unhealthy, mean 42.6 years Health Status: unhealthy Age Group: mean 42.6 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7751528/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 OCT2 779 OCT3 159 MATE1 415 MATE2 267	OCTN1 55 OCTN2 59 OCT1 393 OCT2 434 OCT3 92 MATE1 182 MATE2 98

Drug as perpetrator

Target	Modality	Activity
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 17.4 uM]
OCT3 161	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 2.5 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 3.6 uM]
MATE1 416	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 30.5 uM]
MATE2 267	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 6,21	yes [IC50 62.8 uM]

Drug as victim

Target	Modality	Activity
MATE1 182	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
MATE2 98	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT2 434	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCT3 92	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/27676604/ Page: 7,21	strong
OCTN1 55	substrate 4014 Sources: https://pubs.acs.org/doi/10.1021/mp900206j	yes
OCTN2 59	substrate 4014 Sources: https://pubs.acs.org/doi/10.1021/mp900206j	yes

Sourcing

Vendor/Aggregator	ID	URL
KeyOrganics	KS-5051
Pharmeks	PHAR218016
ZINC	ZINC000013782937	http://zinc15.docking.org/substances/ZINC000013782937

PubMed

Title	Date	PubMed
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].	2002-08-05	12162793
Hospitalizations and mortality in the Lung Health Study.	2002-08-01	12153966
Airways reactivity in patients with CF.	2002-08	12162108
Hospital management of children with acute asthma exacerbations in Kuwait: adherence to international guidelines.	2002-07-26	12138293
Emergency department asthma: compliance with an evidence-based management algorithm.	2002-07	12161875
Management of acute, severe asthma in children.	2002-06-28	12086560
Treatment and quality of life in patients with chronic obstructive pulmonary disease.	2002-06	12086118
The role of anticholinergics in acute asthma treatment: an evidence-based evaluation.	2002-06	12065366
Understanding and use of inhaler medication by asthmatics in specialty care in Trinidad: a study following development of Caribbean guidelines for asthma management and prevention.	2002-06	12065346
[Effect of ipratropium bromide on calcium activated potassium channel in tracheal smooth muscle cells from chronically hypoxic rats].	2002-05	12133322
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?	2002-05	12030735
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease.	2002-04	11998992
Do bronchodilators have an effect on bronchiolitis?	2002-04	11983033
Differential response of wheezes and ruttles to anticholinergics.	2002-04	11919106
Intravenous versus oral corticosteroids for treatment of acute asthma exacerbations.	2002-04	11918500
[Effect of anticholinergic therapy on myocardial reserve dynamics in patients with chronic obstructive bronchitis].	2002-03-08	11881364
Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.	2002-03-01	11874817
Mydriasis due to self-administered inhaled ipratropium bromide.	2002-03	11998922
In children hospitalized for asthma exacerbations, does adding ipratropium bromide to albuterol and corticosteroids improve outcome?	2002-03	11978242
Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD.	2002-03	11888949
Clinical review: severe asthma.	2002-02	11940264
[Benefits of ipratropium bromide in the management of asthmatic crises in the emergency department].	2002-02	11915491
Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department.	2002-02	11889328
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.	2002-02	11871363
Other option in bronchiolitis.	2002-02	11867862
Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice.	2002-02	11819029
Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.	2002-02	11812272
Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen.	2002-02	11812271
Effects of inhaled ipratropium bromide on breathing mechanics and gas exchange in exercising horses with chronic obstructive pulmonary disease.	2002-01	11817550
The incremental shuttle walking test in elderly people with chronic airflow limitation.	2002-01	11809987
[Asthma follow-up after treatment of status asthmaticus in ICU Pneumonology Department in Warsaw Medical University].	2002	12148180
Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing.	2002	12119057
Role of cholinergic reflexes on the bronchoconstrictor reactivity to neurokinin a in allergic dogs.	2002	12090791
Heliox for treatment of exacerbations of chronic obstructive pulmonary disease.	2002	12076487
Histochemical and biochemical studies on the secretory mechanisms of some glands of guinea-pigs treated with histamine.	2002	12056651
Tiotropium bromide.	2002	12010082
[Pharmacodynamics of inhalation broncholytic agents introduced in a single dose by nebulizer in patients with severe exacerbation of bronchial asthma].	2002	11980113
Management of children with severe asthma exacerbation in the emergency department.	2002	11909006
Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.	2002	11869627
Anticholinergic drugs for wheeze in children under the age of two years.	2002	11869598
Pharmacogenetics, pharmacogenomics and airway disease.	2002	11806845
Cold-induced rhinitis in skiers--clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial.	2001-12-06	11732814
Standard dose of inhaled albuterol significantly increases QT dispersion compared to low dose of albuterol plus ipratropium bromide therapy in moderate to severe acute asthma attacks in children.	2001-12	11737740
Randomized trial of the addition of ipratropium bromide to albuterol and corticosteroid therapy in children hospitalized because of an acute asthma exacerbation.	2001-12	11732951
Does adding ipratropium to salbutamol (albuterol) help children with asthma?	2001-11	12035817
Lower arrythmogenic risk of low dose albuterol plus ipratropium.	2001-10	11758131
Drug therapy of childhood asthma.	2001-09	11980463
Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog.	2001-07	11745922
Effect of ipratropium bromide on airway and pulmonary muscarinic receptors in a rat model of chronic obstructive pulmonary disease.	2001-01	11779443
Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing.	2001	11735662

Patents

Sample Use Guides

In Vivo Use Guide

The usual starting dose of ATROVENT® HFA is two inhalations four times a day. Patients may take additional inhalations as required; however, the total number of inhalations should not exceed 12 in 24 hours.

Route of Administration: Oral

In Vitro Use Guide

Ba 679 BR, atropine, and ipratropium bromide inhibited electrical field stimulation (EFS)-induced contraction with IC50 values of 0.17, 0.74, and 0.58 nM, respectively, in guinea pig trachea. Ba 679 BR had a slower onset and longer duration of action than atropine or ipratropium bromide (the times required to attain 50% of the maximum response were 34.8, 3.8, and 7.6 min, respectively, and the times required for 50% recovery of the response were 540, 31.6, and 81.2 min, respectively).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:50:01 GMT 2025` Edited by `admin` on `Mon Mar 31 18:50:01 GMT 2025`
Record UNII	J697UZ2A9J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COMBIVENT COMPONENT IPRATROPIUM BROMIDE

Preferred Name

English

Ipratropium bromide

Official Name

English

(1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide monohydrate

Systematic Name

English

IPRATROPIUM BROMIDE [VANDF]

Common Name

English

IPRATROPIUM BROMIDE [USP MONOGRAPH]

Common Name

English

IPRATROPIUM BROMIDE [USP-RS]

Common Name

English

DUONEB COMPONENT IPRATROPIUM BROMIDE

Common Name

English

IPRATROPIUM BROMIDE HYDRATE [JAN]

Common Name

English

DUOVENT COMPONENT IPRATROPIUM BROMIDE

Brand Name

English

SCH 1000-BR-MONOHYDRATE

Code

English

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, monohydrate, (3-endo,8-syn)-

Systematic Name

English

Ipratropium bromide monohydrate

Common Name

English

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, hydrate (1:1:1), (3-endo,8-syn)-

Systematic Name

English

IPRATROPIUM BROMIDE [ORANGE BOOK]

Common Name

English

NSC-759613

Code

English

IPRATROPIUM BROMIDE [MART.]

Common Name

English

IPRATROPIUM BROMIDE HYDRATE

Common Name

English

8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, monohydrate, (endo,syn)-(±)-

Systematic Name

English

SCH-1000-BR-

Code

English

ATROVENT

Brand Name

English

Ipratropium bromide monohydrate [WHO-DD]

Common Name

English

IPRATROPIUM BROMIDE [USAN]

Common Name

English

IPRATROPIUM BROMIDE [EP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QR01AX03